Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MaxCyte, Inc. - Common Stock
(NQ:
MXCT
)
1.290
-0.010 (-0.77%)
Delayed Quote
Updated: 1:27 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MaxCyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
These stocks have an unusual volume in today's session
↗
October 15, 2026
Via
Chartmill
Top movers analysis in the middle of the day on 2026-10-14: top gainers and losers in today's session.
↗
October 14, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
October 14, 2026
Via
Chartmill
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
October 14, 2026
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback
↗
May 12, 2026
Via
Chartmill
MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook
↗
March 24, 2026
Via
Chartmill
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
September 23, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
Revenue declined 15% year-over-year, but net losses narrowed significantly.
Via
The Motley Fool
Topics
Earnings
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
August 19, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Q2 Earnings Call Highlights
↗
August 12, 2026
MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year...
Via
MarketBeat
Topics
Earnings
MaxCyte Reports Second Quarter 2026 Financial Results
August 12, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
↗
May 13, 2026
Via
Chartmill
MaxCyte Q1 Earnings Call Highlights
↗
May 12, 2026
MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core...
Via
MarketBeat
Topics
Earnings
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
↗
March 24, 2026
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
March 24, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
March 23, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
February 24, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
February 23, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Planned CFO Transition in 2026
November 12, 2025
Company initiates search for successor
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Insights into MaxCyte's Upcoming Earnings
↗
November 11, 2025
Via
Benzinga
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 05, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
